The clinical trials listed on this page should not be construed as being endorsed by HER2 Support Group. You should consult your medical practitioner beforehand if you are interested in participating in any of these trials. Also, these are not the only clinical trials currently available for women who overexpress the HER2/neu gene, but are representative of trials of drugs currently under study. If you are aware of any clinical trials of interest to our group or if you are Healthcare Professional and wish to have a trial listed here please contact: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Vaccines

University of Washington Other Trials at U of W Vaccine Plus Lapatinib Glaxo Smith Kline

Other Noteworthy Trials

Herceptin & Tykerb for Metastatic breast Cancer T-DM1 Trials BOLERO Trials Herceptin plus new Novartis Investigational Drug Tykerb - Adjuvant Theraphy Trials Other Trials of Interest IPI-504 and Herceptin in Metastatic Breast Cancer. In preclinical studies, IPI-504 has demonstrated the potential to disrupt the activity of multiple proteins and cell signaling pathways implicated in tumor growth, including HER2.